Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2208 Target Snapshot

MAP kinase-activated protein kinase 2 · SINGLE PROTEIN · Homo sapiens

3,923Compounds
750Assays
6Approved Drugs
2,985.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

MAP kinase-activated protein kinase 2 shows clinical signal disease relevance led by neoplasm. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49137. Start with neoplasm, then reuse UniProt P49137 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P49137 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
neoplasm

MAP kinase-activated protein kinase 2 shows clinical signal disease relevance led by neoplasm. 1 linked drug remains visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include AT-13148. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MAP kinase-activated protein kinase 2 as ChEMBL target CHEMBL2208, mapped to UniProt P49137. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MAP kinase-activated protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2208
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P49137
MAP kinase-activated protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether MAP kinase-activated protein kinase 2 is the right protein anchor across sources, using UniProt P49137 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMAP kinase-activated protein kinase 2
UniProt AccessionP49137
Component TypeProtein
Sequence Length400 aa

MAP kinase-activated protein kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as MAP kinase-activated protein kinase 2, mapped to UniProt P49137. Sequence length is 400 aa.

Mapped IDP49137
Review nameMAP kinase-activated protein kinase 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

MAP kinase-activated protein kinase 2 shows clinical signal disease relevance led by neoplasm.

Clinical signal Phase I
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugAT-13148
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include AT-13148. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
3
Phase III
16
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC501,547.0
KI775.0
EC50303.0
KD360.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1090090 9.52 Kd 0.3 Clinical
CHEMBL1933189 9.21 EC50 0.62 Preclinical
CHEMBL1933188 9.15 EC50 0.71 Preclinical
CHEMBL1933164 9.14 EC50 0.72 Preclinical
CHEMBL1933166 9.02 EC50 0.96 Preclinical
CHEMBL1801384 9.0 IC50 1.0 Preclinical
CHEMBL1933162 9.0 EC50 1.0 Preclinical
CHEMBL5612036 9.0 IC50 1.0 Preclinical
CHEMBL5613264 9.0 IC50 1.0 Preclinical
CHEMBL561334 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

211
5.0
226
5.5
216
6.0
212
6.5
109
7.0
102
7.5
97
8.0
35
8.5
9
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

LENVATINIB
CHEMBL1289601
Approved 2015
AFATINIB
CHEMBL1173655
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
Assay Landscape

Assay Landscape

750
Total Assays
1,145
Tested Compounds
3
Assay Types
Binding — 738 assays, 1,145 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 590 938 6.5
assay format 100 17 6.6
cell-based format 47 169 5.8
subcellular format 1 21 6.4
Functional — 11 assays, 126 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 10 12 5.5
assay format 1 114 5.7
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine